Comment from Anonymous

Summary: Revvity Health Sciences Inc. supports the proposed reclassification of IGRA devices from Class III to Class II, provided that the FDA implements robust special controls. They argue that because there is no microbiological gold standard for these tests, the FDA must require independent clinical performance data and clear validation expectations to ensure diagnostic reliability and public health safety.